While similar concerns have been raised in CML (20), this is, to our knowledge, the first report of primary TKI resistance in chronic-phase PDGFRB-rearranged MLN associated with high-risk mutations and adverse outcome. This evidence concerns the gene PDGFRB and chronic myelogenous leukemia, BCR-ABL1 positive.